Medicines, medical devices and blood regulation and safety

Services

See all services

Guidance and regulation

See all guidance and regulation

News and communications

  1. Xofigo▼ (radium-223-dichloride): new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial
  2. Daclizumab beta (Zinbryta▼): risk of immune-mediated encephalitis – some cases several months after stopping treatment
  3. Nusinersen (Spinraza▼): reports of communicating hydrocephalus; discuss symptoms with patients and carers and investigate urgently
  4. Letters and drug alerts sent to healthcare professionals in August 2018
See all news and communications

Research and statistics

See all research and statistics

Policy and engagement

See all policy and engagement

Transparency

See all transparency